Opus Genetics Management

Management Kriterienprüfungen 2/4

Opus Genetics CEO ist George Magrath , ernannt in Nov 2023, hat eine Amtszeit von 2.08 Jahren. Die jährliche Gesamtvergütung beträgt $889.24K , bestehend aus 64.7% Gehalt und 35.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.1% der Aktien des Unternehmens, im Wert von $1.55M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2 Jahre bzw. 5.1 Jahre.

Wichtige Informationen

George Magrath

Geschäftsführender

US$889.2k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	64.66%
Amtszeit als Geschäftsführer	2.1yrs
Eigentum des Geschäftsführers	1.1%
Durchschnittliche Amtszeit des Managements	2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.1yrs

Jüngste Management Updates

Recent updates

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Dec 11

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Sep 09

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Jul 11

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

May 19

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Apr 09

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Aug 19

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Jul 24

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Jul 12

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

May 02

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Mar 15

Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

May 20

Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%

Apr 02

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Jan 27

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von George Magrath im Vergleich zu den Einnahmen von Opus Genetics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2025	n/a	n/a	-US$68m
Jun 30 2025	n/a	n/a	-US$58m
Mar 31 2025	n/a	n/a	-US$59m
Dec 31 2024	US$889k	US$575k	-US$58m
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$96k	-US$10m

Vergütung im Vergleich zum Markt: GeorgeDie Gesamtvergütung ($USD889.24K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD575.90K).

Entschädigung vs. Einkommen: GeorgeDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

George Magrath (41 yo)

2.1yrs

Amtszeit

US$889,238

Vergütung

Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment Research Limited si...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
George Magrath	CEO & Director	2.1yrs	US$889.24k	1.1% $ 1.6m
Benjamin Yerxa	President & Director	1.2yrs	keine Daten	0.10% $ 141.6k
Ashwath Jayagopal	Chief Scientific & Development Officer	1.8yrs	US$1.24m	0.025% $ 34.8k
Robert Gagnon	CFO & Principal Accounting Officer	less than a year	keine Daten	keine Daten
Joseph Schachle	Chief Operating Officer	2.1yrs	keine Daten	0.0029% $ 4.1k
Jenny Kobin	Investor Relations Officer	no data	keine Daten	keine Daten
Bernhard Hoffmann	Senior Vice President of Corporate Development & Secretary	no data	US$789.92k	0.17% $ 240.0k
Bindu Manne	Head of Market Development & Commercialization	3.9yrs	keine Daten	keine Daten
Sally Tucker	Senior Vice President of Clinical Development	no data	keine Daten	keine Daten
Erik Sims	Director & Corporate Controller	no data	keine Daten	keine Daten

2.0yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: IRDDas Führungsteam des Unternehmens gilt nicht als erfahren ( 2 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
George Magrath	CEO & Director	2.1yrs	US$889.24k	1.1% $ 1.6m
Benjamin Yerxa	President & Director	no data	keine Daten	0.10% $ 141.6k
James S. Manuso	Independent Director	5.1yrs	US$184.43k	0.20% $ 287.9k
Adrienne Graves	Independent Director	1.2yrs	US$192.82k	keine Daten
David Boyer	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Richard Rodgers	Independent Director	5.1yrs	US$267.48k	0.35% $ 487.9k
Susan Benton	Independent Director	5.1yrs	US$176.39k	0.20% $ 285.7k
Cameron Gallagher	Independent Chairman	5.1yrs	US$219.61k	2.51% $ 3.5m
Sean Ainsworth	Lead Independent Director	5.1yrs	US$200.22k	0.25% $ 357.6k
Jean Bennett	Director	1.2yrs	US$325.82k	0.049% $ 69.4k
Arshad Khanani	Member of Medical Advisory Board	1.8yrs	keine Daten	keine Daten
Mark Pennesi	Member of Medical Advisory Board	no data	keine Daten	keine Daten

5.1yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrener Vorstand: IRDDie Vorstandsmitglieder gelten als erfahren (5.1 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/12/26 02:24
Aktienkurs zum Tagesende	2025/12/24 00:00
Gewinne	2025/09/30
Jährliche Einnahmen	2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Opus Genetics, Inc. wird von 9 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
James Molloy	Alliance Global Partners
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Kumaraguru Raja	Brookline Capital Markets

Opus Genetics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

CEO & Director recently bought US$98k worth of stock

CEO & Director recently bought US$101k worth of stock

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Recent updates

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Consensus EPS estimates fall by 16%, revenue upgraded

Third quarter 2025 earnings: EPS misses analyst expectations

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics, Inc. Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $23 million.

Price target increased by 13% to US$6.80

New major risk - Revenue and earnings growth

Opus Genetics, Inc. Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Opus Genetics, Inc. Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured At Medical and Industry Conferences in September

Opus Genetics, Inc. announced that it has received $3.5 million in funding

Consensus revenue estimates decrease by 18%, EPS upgraded

Opus Genetics Announces FDA Clearance of Ind Application for Gene Therapy Candidate OPGx-Best1

New major risk - Financial position

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc. Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Consensus revenue estimates increase by 16%

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5

Price target decreased by 13% to US$9.25

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Consensus revenue estimates increase by 34%

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

Opus Genetics, Inc. announced that it has received $1.500001 million in funding

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Opus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital Amaurosis

New major risk - Shareholder dilution

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

CEO & Director recently bought US$98k worth of stock

Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

CEO & Director recently bought US$101k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 21% to US$13.67

Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Consensus revenue estimates increase by 62%

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 12% to US$17.25

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Full year 2023 earnings: EPS and revenues miss analyst expectations

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Investor sentiment improves as stock rises 17%

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors